<DOC>
	<DOCNO>NCT01100866</DOCNO>
	<brief_summary>This randomize , two-arm , placebo control trial evaluate benefit treatment use POMELLA™ extract mechanism know drive prostate cancer . This research allow provision biochemical histological comparison make POMELLA™ treat placebo treat prostate tissue remove men organ confine prostate cancer .</brief_summary>
	<brief_title>Study POMELLA™ Extract Treat Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men 18 year old ( 19 year BC ) histologic diagnosis clinically localized prostate cancer prior radical prostatectomy define : 1 . Clinical state T1T2 2 . PSA &lt; 20 3 . Gleason score ≤ 7 ECOG performance status 01 . Life expectancy great 10 year . Able understand give inform consent . Laboratory value must follow : 1 . White blood cell count : ≥ 3,000/mm^3 2 . Absolute granulocyte count : ≥ 1,500/mm^3 3 . Platelets : ≥ 100,000/mm^3 4 . Hemoglobin : ≥ 12g/dL 5 . Serum creatinine : ≤ 1.5 x ULN 6 . AST : ≤ 2 x ULN 7 . ALT : ≤ 2 x ULN 8 . Serum calcium : ≤ ULN 9 . Total bilirubin : ≤ 1.5 x ULN Patients receive investigational therapy . Patients receive receive treatment prostate cancer . Patients active serious infection serious underlie medical condition would otherwise impair ability receive protocol treatment . Dementia significantly alter mental status would prohibit understanding and/or give informed consent . Histologic evidence small cell carcinoma prostate . Patients currently receive active therapy neoplastic disorder eligible study . Patients receive androgen , estrogens progestational agent . Patients know hypersensitivity pomegranates composite capsules/placebo : hydroxypropyl methylcellulose , silicon dioxide aerosol . Patients take drug natural health product might impact biochemical test ( example include : spironolactone , aprepitant , bexarotene , clarithromycin , itraconazole , ketoconazole , St. John 's wort ) . A washout period 30 day prior commence study would necessary compound require . Patients chronic active hepatitis . Medical condition , , opinion investigator would jeopardize either patient integrity data obtain .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>clinically localized Prostate Cancer</keyword>
	<keyword>low intermediate risk relapse</keyword>
	<keyword>candidate radical prostatectomy</keyword>
</DOC>